Display options
Cite
Blueschke G, Boico A, Negussie AH, et al. Enhanced Drug Delivery to the Skin Using Liposomes. Plast Reconstr Surg Glob Open. 2018;6(7):e1739doi: 10.1097/GOX.0000000000001739.
Blueschke, G., Boico, A., Negussie, A. H., Yarmolenko, P., Wood, B. J., Spasojevic, I., Fan, P., Erdmann, D., Schroeder, T., Sauerbier, M., & Klitzman, B. (2018). Enhanced Drug Delivery to the Skin Using Liposomes. Plastic and reconstructive surgery. Global open, 6(7), e1739. https://doi.org/10.1097/GOX.0000000000001739
Blueschke, Gert, et al. "Enhanced Drug Delivery to the Skin Using Liposomes." Plastic and reconstructive surgery. Global open vol. 6,7 (2018): e1739. doi: https://doi.org/10.1097/GOX.0000000000001739
Blueschke G, Boico A, Negussie AH, Yarmolenko P, Wood BJ, Spasojevic I, Fan P, Erdmann D, Schroeder T, Sauerbier M, Klitzman B. Enhanced Drug Delivery to the Skin Using Liposomes. Plast Reconstr Surg Glob Open. 2018 Jul 09;6(7):e1739. doi: 10.1097/GOX.0000000000001739. eCollection 2018 Jul. PMID: 30175003; PMCID: PMC6110675.
Copy Download .nbib Format: NLM
Share it on

Plast Reconstr Surg Glob Open. 2018 Jul 09;6(7):e1739. doi: 10.1097/GOX.0000000000001739. eCollection 2018 Jul.

Enhanced Drug Delivery to the Skin Using Liposomes.

Plastic and reconstructive surgery. Global open

Gert Blueschke, Alina Boico, Ayele H Negussie, Pavel Yarmolenko, Bradford J Wood, Ivan Spasojevic, Ping Fan, Detlev Erdmann, Thies Schroeder, Michael Sauerbier, Bruce Klitzman

Affiliations

  1. Kenan Plastic Surgery Research Labs, Duke University Medical Center, Durham, N.C.
  2. Department of Radiation Oncology, Duke University Medical Center, Durham, N.C.
  3. Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Md.
  4. Department of Biomedical Engineering, Duke University, Durham, N.C.
  5. PK/PD Bioanalytical Core Laboratory, Department of Medicine, Duke University Medical Center, Durham, N.C.
  6. Department of Physical Chemistry, University of Mainz, Mainz, Germany.
  7. Department of Plastic, Hand and Reconstructive Surgery, Hand Trauma Center, BG Trauma Center Frankfurt am Main, Frankfurt, Germany.

PMID: 30175003 PMCID: PMC6110675 DOI: 10.1097/GOX.0000000000001739

Abstract

BACKGROUND: Enhancing drug delivery to the skin has importance in many therapeutic strategies. In particular, the outcome in vascularized composite allotransplantation mainly depends on systemic immunosuppression to prevent and treat episodes of transplant rejection. However, the side effects of systemic immunosuppression may introduce substantial risk to the patient and are weighed against the expected benefits. Successful enhancement of delivery of immunosuppressive agents to the most immunogenic tissues would allow for a reduction in systemic doses, thereby minimizing side effects. Nanoparticle-assisted transport by low temperature-sensitive liposomes (LTSLs) has shown some benefit in anticancer therapy. Our goal was to test whether delivery of a marker agent to the skin could be selectively enhanced.

METHODS: In an in vivo model, LTSLs containing doxorubicin (dox) as a marker were administered intravenously to rats that were exposed locally to mild hyperthermia. Skin samples of the hyperthermia treated hind limb were compared with skin of the contralateral normothermia hind limb. Tissue content of dox was quantified both via high-performance liquid chromatography and via histology in skin and liver.

RESULTS: The concentration of dox in hyperthermia-treated skin was significantly elevated over both normothermic skin and liver. (

CONCLUSIONS: We show here that delivery of therapeutics to the skin can be targeted and enhanced using LTSLs. Targeting drug delivery with this method may reduce the systemic toxicity seen in a systemic free-drug administration. Development of more hydrophilic immunosuppressants in the future would increase the applicability of this system in the treatment of rejection reactions in vascularized composite allotransplantation. The treatment of other skin condition might be another potential application.

References

  1. Transplant Proc. 2001 Feb-Mar;33(1-2):1722 - PubMed
  2. Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):269-76 - PubMed
  3. Biochim Biophys Acta. 1986 May 9;857(1):123-6 - PubMed
  4. Clin Plast Surg. 2012 Oct;39(4):425-34 - PubMed
  5. Am J Transplant. 2007 May;7(5):1304-7 - PubMed
  6. Am J Transplant. 2008 Jul;8(7):1396-400 - PubMed
  7. Clin Plast Surg. 2007 Apr;34(2):271-8, ix-x - PubMed
  8. Transplantation. 2006 Dec 27;82(12):1610-5 - PubMed
  9. Transplantation. 2003 Aug 27;76(4):688-93 - PubMed
  10. J Control Release. 2010 Apr 19;143(2):265-73 - PubMed
  11. Transplant Proc. 2009 Mar;41(2):531-6 - PubMed
  12. Cancer Res. 2000 Dec 15;60(24):6950-7 - PubMed
  13. Theranostics. 2013 May 20;3(6):409-19 - PubMed
  14. Transpl Int. 2011 Aug;24(8):760-9 - PubMed
  15. Semin Plast Surg. 2010 Feb;24(1):11-7 - PubMed
  16. Int J Hyperthermia. 2011;27(2):140-55 - PubMed
  17. Open Nanomed J. 2011 Jan 1;3:38-64 - PubMed
  18. Surg Oncol Clin N Am. 2013 Jul;22(3):545-61 - PubMed
  19. Cancer Res. 2012 Nov 1;72(21):5566-75 - PubMed
  20. Cancer Res. 2000 Mar 1;60(5):1197-201 - PubMed
  21. Cold Spring Harb Perspect Med. 2014 Mar 01;4(3):null - PubMed
  22. Adv Drug Deliv Rev. 2001 Dec 31;53(3):285-305 - PubMed
  23. Transplantation. 2010 Dec 27;90(12):1590-4 - PubMed
  24. Int J Hyperthermia. 2008 Feb;24(1):79-90 - PubMed
  25. Clin Cancer Res. 2006 Jul 1;12(13):4004-10 - PubMed
  26. Lancet. 2003 Jun 28;361(9376):2173-6 - PubMed
  27. J Photochem Photobiol B. 2017 May;170:65-69 - PubMed
  28. Int J Hyperthermia. 2008 Sep;24(6):475-82 - PubMed
  29. Clin Cancer Res. 2006 Nov 15;12(22):6800-7 - PubMed

Publication Types

Grant support